UroGen Pharma Ltd. filed a Form 8-K on August 20, 2026, disclosing that on August 18, 2026, it entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd. and agreed to invest up to $7,000,000 in IntraGel's equity securities.
Key Highlights
- Option Agreement signed: UroGen Pharma, through its wholly owned subsidiary UroGen Pharma, Inc., entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd. on August 18, 2026.
- Exclusive option for head and neck cancer: UroGen U.S. obtained an exclusive option to license IntraGel's TumoCure product, formulated with IntraGel's proprietary biodegradable hydrogel SRGel platform, for the treatment of advanced head and neck cancer.
- Additional product options: The agreement also includes options to obtain exclusive, worldwide licenses for additional products combining IntraGel's SRGel platform with compounds to be designated by UroGen U.S.
- Non-exclusive research license: UroGen U.S. received a non-exclusive license to research and evaluate IntraGel's SRGel platform.
- Equity investment commitment: UroGen Pharma agreed to invest up to $7,000,000 in IntraGel's equity securities under a Securities Purchase Agreement, also dated August 18, 2026.
UroGen Pharma's Option and Investment Agreement with IntraGel Therapeutics
According to the filing, UroGen Pharma Ltd. (NASDAQ:URGN), acting through its wholly owned subsidiary UroGen Pharma, Inc. ("UroGen U.S."), entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd., a company organized under the laws of Israel. The agreement was executed on August 18, 2026, and the 8-K was signed and filed on August 20, 2026, by Chris Degnan, Chief Financial Officer.
The filing discloses that under the Option Agreement, UroGen U.S. obtained three distinct rights from IntraGel. First, it received an exclusive option to obtain an exclusive, worldwide license covering certain IntraGel intellectual property rights to develop, commercialize, and exploit IntraGel's TumoCure product, formulated with IntraGel's proprietary biodegradable hydrogel sustained-release delivery platform, referred to collectively as the "SRGel platform," for the treatment of advanced head and neck cancer. Second, UroGen U.S. received options to obtain exclusive, worldwide licenses for additional products that combine the SRGel platform with compounds to be designated by UroGen U.S. Third, UroGen U.S. received a non-exclusive license to research and evaluate the SRGel platform.
Separately, also on August 18, 2026, the company entered into a Securities Purchase Agreement with IntraGel, under which the company agreed to invest up to $7,000,000 in IntraGel's equity securities, according to the filing. The filing was made under Item 8.01 (Other Events) of Form 8-K. UroGen Pharma's ordinary shares carry a par value of NIS 0.01 per share and are listed on The Nasdaq Stock Market LLC.
What Was Disclosed
UroGen Pharma disclosed the signing of an option and research license agreement with IntraGel Therapeutics granting rights related to IntraGel's SRGel platform, along with a commitment to invest up to $7,000,000 in IntraGel's equity securities, all effective August 18, 2026.




Please wait processing your request...